Antonio Riccardo Buonomo

Plain English
This study looked at how well a treatment called sotrovimab works alongside antiviral medications to help patients with weakened immune systems clear the COVID-19 virus more quickly. Out of 98 patients, those who received both sotrovimab and antiviral treatment cleared the virus faster, with a median time of 17 days. Specifically, starting treatment within 3 days of symptoms and using sotrovimab were linked to quicker recovery, making early intervention important for these patients. Who this helps: This research benefits immunocompromised patients with COVID-19.

Plain English
This paper looked at the safety and effectiveness of COVID-19 treatments for pregnant women, who face heightened risks during the pandemic but have been mostly left out of major drug trials. The review found that the best options for preventing COVID-19 complications are vaccination, while antiviral treatments like nirmatrelvir/ritonavir can help outpatients, and a combination of remdesivir and corticosteroids works for hospitalized patients needing oxygen. This is important because it provides crucial guidance for treating pregnant women with COVID-19 safely. Who this helps: This helps pregnant women with COVID-19 and their healthcare providers.

Plain English
This study looked at 17 adults in Rome who have both allergies and long COVID, focusing on specific biomarkers related to allergic inflammation and the integrity of bodily barriers. The researchers found that participants had varying levels of these biomarkers, with an average blood eosinophil count of about 179 cells per microliter and total immunoglobulin E (IgE) levels averaging 165.4 kU/L. Those with higher levels of a specific marker (ECP) and free light chains reported more severe long COVID symptoms, such as fatigue and difficulty breathing, lasting more than six months. Who this helps: This research is beneficial for patients with allergies and long COVID, as it could guide treatment options.

Plain English
This study looked at whether giving immunocompromised patients with mild-to-moderate COVID-19 a combination of sotrovimab and an antiviral medication (either remdesivir or nirmatrelvir/ritonavir) early in their illness could help prevent severe outcomes. Researchers followed 52 patients and found that none needed hospitalization, oxygen treatment, or died within the first 60 days, and most showed improvement by day 14 after treatment. This is important because it suggests this combination therapy can effectively protect vulnerable patients from more serious illnesses and long-term COVID-19 effects. Who this helps: This helps immunocompromised patients dealing with COVID-19.

Plain English
This study looked at how well molnupiravir (MNP) works in helping patients with COVID-19 avoid serious problems like being hospitalized, needing intensive care, or dying. The researchers found that out of 1382 patients, those treated with molnupiravir had a lower chance of facing serious outcomes compared to those who didn't receive the drug, especially among unvaccinated patients. This is important because it shows that molnupiravir can be a valuable treatment option for people at higher risk of severe illness from COVID-19. Who this helps: This helps patients with COVID-19, especially those who are unvaccinated or at high risk.

Plain English
The paper focuses on Hepatitis D virus (HDV) infection, which is a severe liver disease affecting millions worldwide, though many cases go unreported. The study highlights that screening for HDV in people already infected with Hepatitis B could help find more cases, as over half of those with HDV don't have known risk factors. A new treatment called Bulevirtide was approved in 2020, offering hope for better management of this disease, although more research is needed to fully understand its effects. Who this helps: This helps patients with HDV infection and their healthcare providers.

Plain English
In August and September 2024, an outbreak of West Nile Virus (WNV) infections occurred in Campania, Italy, marking the first human cases in southern Italy. There were five confirmed and seven probable cases, mostly affecting elderly men with other health issues. While most patients experienced severe symptoms, the use of remdesivir in some cases seemed to help reduce hospital stays and improve recovery, with only two deaths linked to secondary infections. Who this helps: This research benefits patients at risk of WNV, especially the elderly and those with health conditions.

Plain English
This study looked at a rare condition called eosinophilic ascites (EA), which occurs when there is a high number of eosinophils, a type of white blood cell, in the fluid in the abdomen. The researchers found three patients at their hospital with EA linked to eosinophilic gastrointestinal diseases (EGIDs) and reviewed a total of 105 similar cases documented in scientific literature. These findings matter because EA can indicate serious underlying health issues, and recognizing it early can lead to effective treatments, like steroids and specific medications targeting eosinophils. Who this helps: Patients with eosinophilic gastrointestinal diseases and their doctors.

Plain English
This study looked at how common allergic reactions are among cancer patients using platinum-based drugs and taxanes, which are typical cancer treatments. Researchers evaluated 276 patients and found that 114 of them had positive allergy skin tests, with 64% of those reactions linked to platinum compounds compared to only 9.9% for taxanes. These findings show that allergy testing is crucial because it helps doctors choose the right treatments for patients who experience these reactions. Who this helps: This benefits cancer patients who may need alternative therapies if they have allergies to specific chemotherapy drugs.

Plain English
This study examined how adults with severe asthma who did not improve on other treatments responded after switching to the medication dupilumab. After one year, results showed that lung function improved by about 10.8%, levels of certain inflammatory markers dropped significantly, and 20% of patients achieved complete remission. This is important because it indicates that switching to dupilumab can be an effective option for people struggling with severe asthma who haven't done well with other medications. Who this helps: This helps patients with severe asthma who haven't responded well to their initial treatments.

Plain English
This study looked at allergic reactions to a drug called ocrelizumab, which is used to treat multiple sclerosis. Out of 387 patients, 94 experienced infusion-related reactions, and 6 cases were identified as IgE-mediated allergic reactions, meaning they were triggered by the immune system's response to the drug. Patients with a history of allergies were more likely to have these reactions, and switching to another drug called ofatumumab was generally safe and well-tolerated for those affected. Who this helps: Patients with multiple sclerosis and a history of allergies who are being treated with ocrelizumab.

Plain English
This study looked at how well a treatment called casirivimab/imdevimab worked for 12 unvaccinated pregnant women who had mild-to-moderate COVID-19. After receiving the treatment, none of the women experienced severe side effects, and none progressed to severe COVID-19. This matters because it shows that the treatment can be safely used to help prevent serious illness in pregnant women dealing with mild-to-moderate COVID-19. Who this helps: This helps unvaccinated pregnant women with COVID-19.

Plain English
This study looked at a rare infection of the spine called spondylodiscitis and how the drug rezafungin can be used to treat it, especially when other treatments don't work. A 68-year-old patient who had difficulty tolerating traditional antifungal treatments received weekly doses of rezafungin for 26 weeks and experienced a complete recovery without any side effects. This finding is important because it shows that rezafungin could be a valuable option for patients with serious infections who don't respond well to standard therapies. Who this helps: Patients with difficult-to-treat spine infections.

Plain English
This study looked at how COVID-19 affected patients with thymic epithelial tumors (TETs), particularly those with a related condition called Good's syndrome (GS), which weakens the immune system. Out of 47 TET patients, 31 (66%) contracted COVID-19, and among those, 18 had GS. The severity of COVID-19 was notably higher in patients with GS, with 45% experiencing severe symptoms compared to only 7.7% in patients without GS. Who this helps: This research benefits TET patients, especially those with Good's syndrome, by highlighting the need for careful monitoring and tailored treatment.

Plain English
This study looked at two cases of advanced malignant uterine PEComa, a rare type of tumor. The first patient, a 74-year-old woman, had a large mass and possible metastasis in her liver, while the second patient, a 50-year-old woman, had a smaller uterine mass with potential lung and liver spread. The second patient was successfully treated with a specific therapy, showing no recurrence after eight months, highlighting the need for better diagnostic methods since PEComas can be confused with other tumor types. Who this helps: This helps patients with PEComa and their doctors in understanding the diagnosis and treatment options.

Plain English
This study looked at a specific drug called SonoVue, which is used during ultrasound procedures to improve the quality of images by making fluids easier to see. The researchers shared a case where a patient had a severe allergic reaction (anaphylaxis) after receiving SonoVue and reviewed 13 other similar cases found in the literature. They found that it is crucial for medical professionals to recognize and respond quickly to these dangerous reactions, as SonoVue is widely used. Who this helps: This helps doctors and healthcare providers who administer SonoVue to be better prepared for potential allergic reactions in patients.

Plain English
This study looked at a new antibiotic called oritavancin for treating a shoulder infection related to a prosthetic joint. The researchers followed an elderly man who, despite having a tough-to-treat infection caused by a resistant bacteria, received oritavancin for 28 weeks. He experienced no side effects, his pain went away, and he regained movement in his shoulder, without needing more surgery or hospital visits. Who this helps: This helps patients with joint infections caused by resistant bacteria, especially those who can't undergo surgery.

Plain English
This study looked at a 42-year-old man who had a kidney transplant and was also infected with hepatitis B and hepatitis delta viruses. After receiving bulevirtide, a new antiviral treatment, for 6 months, his hepatitis delta virus levels dropped to undetectable after just 2 months, and his liver function tests returned to normal. This is important because it shows that bulevirtide can be effective and safe for people with hepatitis delta virus who have had organ transplants, which has been a challenging group to treat. Who this helps: This benefits kidney transplant patients infected with hepatitis delta virus.

Plain English
This study looked at how effective different antibiotic treatments are for patients with infections caused by a tough-to-treat bacteria called carbapenem-resistant Acinetobacter baumannii (CRAB). Out of 45 patients, those treated with a drug called cefiderocol had a much higher success rate in improving their condition—100% success compared to just 63% for those treated with another drug, colistin. This matters because finding effective treatments for CRAB infections is critical, given their high mortality rates and limited treatment options. Who this helps: This helps patients with CRAB infections and the doctors treating them.

Plain English
This study looked at how effective the antiviral drug nirmatrelvir/ritonavir (N/r) is in preventing severe outcomes from COVID-19 in patients infected with the omicron variant. Researchers found that out of 1,064 patients, those treated with N/r had much lower death rates (0.5%) compared to those who weren't treated (7.8%). This treatment is especially helpful for unvaccinated patients, as it reduced their risk of hospitalization and death. Who this helps: This helps patients with COVID-19, especially those who are unvaccinated or at high risk for severe illness.

Plain English
This study looks at how the bacteria in the gut, known as the gut microbiota, are affected by Hepatitis C Virus (HCV) and how treatments called direct-acting antivirals (DAAs) can improve patient health. Researchers found that HCV changes gut bacteria, which can lead to more liver disease, but DAAs not only help eliminate the virus but can also positively influence gut bacteria. Understanding these changes could lead to new treatments for liver disease related to HCV. Who this helps: This helps patients with Hepatitis C, particularly those dealing with liver disease.

Plain English
This study looked at how common invasive fungal infections (IFIs) are in COVID-19 patients who were hospitalized but not in intensive care. Out of 409 patients, there were 18 cases of different types of IFIs, mainly among those receiving high doses of steroids for extended periods, leading to a longer hospital stay (63 days compared to 24 days) and a higher death rate (23% vs. 7%) for those with IFIs. This matters because it highlights the need for doctors to be alert for fungal infections in severely ill COVID-19 patients, as these infections can significantly worsen their condition. Who this helps: This helps patients with severe COVID-19 and their healthcare providers.

Plain English
This study looked at how diabetes affects the severity of COVID-19 and whether antidiabetic treatments can make a difference. Researchers found that people with diabetes often have worse outcomes when infected with the virus, but those who received antidiabetic treatment had a better chance of recovery. This matters because improving diabetes management could help reduce the serious effects of COVID-19 in these patients. Who this helps: This helps patients with diabetes and healthcare providers managing their care.

Plain English
This study looked at 14 hospitalized patients with severe COVID-19 who were treated with a combination of two medications: casirivimab/imdevimab and remdesivir. The results showed that all but one patient improved within a week, and all were discharged in good condition, with no negative side effects reported. This matters because it suggests that combining these two treatments can be safe and effective for patients with severe COVID-19. Who this helps: This helps patients with severe COVID-19 and the doctors treating them.

Plain English
This study looked at how treating hepatitis C (HCV) affects the immune system in patients also infected with HIV. Researchers found that after using direct antiviral treatments, the number of CD4+ T cells, which are crucial for fighting off infections, did not change significantly in these patients. This matters because even though the HCV was successfully eliminated, the immune response related to HIV remained stable, indicating that HCV treatment alone doesn't improve the immune function in HIV-HCV co-infected patients. Who this helps: This research benefits patients with both HIV and HCV by providing insights into their treatment outcomes.

Plain English
This study focused on the effectiveness of the antiviral drug remdesivir, both alone and combined with monoclonal antibodies, in preventing severe COVID-19 in patients who have mild to moderate symptoms and are at high risk of serious illness. Out of 62 patients treated, only 8% were hospitalized, and the rates of serious complications like needing extra oxygen or intensive care were very low, at 3.2% and 1.6%, respectively. These results indicate that early treatment with remdesivir can help protect vulnerable patients from worsening illness. Who this helps: Patients with mild to moderate COVID-19, especially those at high risk for severe disease.

Plain English
This study looked at how COVID-19 affected solid organ transplant recipients more than two years into the pandemic, focusing on the effectiveness of new antiviral treatments. Out of 40 patients studied, those who received antiviral therapies and monoclonal antibodies early in their COVID-19 infections had improved outcomes, including lower rates of severe illness. Additionally, it was found that some medications used to suppress the immune system might worsen or help with COVID-19 severity, and getting vaccinated, especially with a booster, was crucial for better health outcomes. Who this helps: This benefits solid organ transplant patients and their healthcare providers.

Plain English
This study looked at how well the antibiotic ceftobiprole works in treating pneumonia and other infections in 195 patients across 10 hospitals in Italy. Researchers found that ceftobiprole successfully treated 79% of the patients who could be evaluated, with a 20% overall death rate. These findings are important because they confirm that ceftobiprole is a safe and effective treatment option for pneumonia and other infections in everyday clinical settings. Who this helps: This helps patients with pneumonia and other infections, as well as their doctors making treatment decisions.

Plain English
This study examined how treating patients with hepatitis C with a new type of antiviral medication affects the bacteria living in their intestines. Researchers treated 12 patients for 12 weeks, and all of them successfully cleared the virus. They found that after treatment, there was a reduction in harmful bacteria and an increase in the diversity of healthy gut bacteria, especially in those without severe liver damage. Who this helps: This benefits patients with hepatitis C, particularly those undergoing treatment for liver issues.

Plain English
This study looked at the effectiveness of cefiderocol, a new antibiotic, in treating infections caused by a tough bacteria called Acinetobacter baumannii, which is resistant to many other antibiotics. Out of 38 patients treated, 30-day mortality was high at 47.5%, and while treatment outcomes improved over time, nearly half (47.5%) of the patients showed clinical failure after 7 days. The results suggest that cefiderocol can work on these infections, even when used alone, but more research is needed to find the best treatment options. Who this helps: This helps patients with difficult-to-treat bacterial infections, doctors seeking effective treatments, and healthcare providers managing antibiotic resistance issues.

Plain English
This research looked at a serious post-surgery complication called vaginal cuff dehiscence (VCD), which can happen after procedures like hysterectomies. The study presented two cases of older women who experienced this condition, leading to serious issues after surgery. The findings indicated that closing the vaginal cuff using a laparoscopic method is better at preventing VCD compared to other techniques. Who this helps: This information helps doctors and surgeons perform safer surgeries and recognize risks for their patients.

Plain English
This study looked at the risk of a specific type of pneumonia in patients who were hospitalized for COVID-19, focusing on those who do not have HIV. Researchers found that among the 54 patients studied, 18 developed this pneumonia, and those with it had lower immune cell counts, longer COVID-19 infections, received higher doses of steroids, and were less likely to be vaccinated than those without pneumonia. The key takeaway is that the amount of steroids given to COVID-19 patients can increase the risk of developing this pneumonia, regardless of whether they had other immune issues. Who this helps: This information is useful for doctors treating COVID-19 patients, especially when considering steroid treatments.

Plain English
This study looked at allergic reactions in cancer patients who were treated with a drug called paclitaxel, finding that about 6% of gynecologic cancer patients and 4% of breast cancer patients experience immediate hypersensitivity reactions (iHSRs). Researchers developed a new test, called a basophil activation test (BAT), which shows promise in identifying these allergic reactions; it was able to correctly identify 90.91% of patients with reactions to paclitaxel and 78.57% of those with reactions to another drug called carboplatin. This is important because it could help improve how doctors manage drug allergies in cancer patients by offering better diagnostic tools. Who this helps: Patients undergoing cancer treatment.

Plain English
This study looked at whether patients with COVID-19 pneumonia who have normal immune systems carry a fungal infection called PJP. Out of 290 patients examined, only 1 patient (1.7%) tested positive for PJP, and that person was the only one to develop the infection later. These findings are important because they show that PJP is rare in otherwise healthy COVID-19 patients, which can help doctors better assess risk and manage treatment. Who this helps: This helps patients and doctors understand the risk of fungal infections in COVID-19 cases.

Plain English
This study looked at kidney transplant patients to see how the use of mTOR inhibitors—a type of medication that suppresses the immune system—affected their outcomes if they contracted COVID-19. Out of 371 patients, 56 (about 15%) got COVID-19, but those on mTOR inhibitors had a 20% lower chance of developing moderate or severe illness compared to those on other treatments. These findings are important because they suggest that mTOR inhibitors may improve COVID-19 outcomes in kidney transplant recipients. Who this helps: This benefits kidney transplant patients by potentially improving their health during COVID-19.

Plain English
This study looked at how well adults with allergies to lipid transfer proteins (found in many plants) used their prescribed epinephrine auto-injectors for allergic reactions. Out of 165 patients, only 1.7% used their auto-injector, even though 68 allergic reactions were recorded over three years, mostly mild but some severe. The findings highlight that many patients were prescribed auto-injectors unnecessarily, showing a need for better monitoring to ensure patients understand how and when to use them. Who this helps: This helps patients with food allergies and their doctors.

Plain English
The COPE study looked at how socio-economic factors, like income inequality and living conditions, affected the spread of COVID-19 within households in the Campania region of Southern Italy. Researchers interviewed 413 people with COVID-19 and found that higher age, existing health problems, living in crowded homes, and renting instead of owning a home were linked to a more than 50% chance of spreading the virus among family members. This is important because it highlights that poorer living conditions can increase COVID-19 transmission, helping to target support where it’s needed most. Who this helps: This helps patients and public health officials in areas with high income inequality.

Plain English
This study looked at how well two oral antiviral medications, nirmatrelvir/ritonavir and molnupiravir, work in treating COVID-19 during the omicron variant surge in Italy. Out of 257 patients, 57% took molnupiravir and 43% took nirmatrelvir/ritonavir. The researchers found that only 2.1% of those on molnupiravir and 0.9% of those on nirmatrelvir/ritonavir ended up in the hospital, while the average time to clear the virus was shorter for nirmatrelvir/ritonavir users (8 days) compared to molnupiravir users (10 days). This is important because it shows that both treatments were safe and effective, leading to fewer complications than previously reported in clinical trials. Who this helps: This helps patients with COVID-19, particularly those at risk for severe illness.

Plain English
This study looked at how the rate of cesarean sections (C-sections) changed over time for pregnant women with COVID-19 at a hospital in Italy. It found that the overall C-section rate decreased from 68.5% in early 2020 to 57.4% by late 2021, and that women in specific categories also had lower C-section rates as the pandemic progressed. Additionally, the number of induced labor cases increased, indicating that the care and management of pregnant women with COVID-19 improved over the course of the pandemic. Who this helps: This benefits pregnant women with COVID-19 and the healthcare providers caring for them.

Plain English
This study examined how effective monoclonal antibodies (mAbs) are in treating patients at high risk for severe COVID-19 before the omicron variant appeared. Among 185 patients treated, only 9.2% experienced severe outcomes like hospitalization or death, but those with chronic kidney disease or high D-dimer levels were at greater risk. These findings are important because they demonstrate that mAbs can help protect vulnerable patients from severe disease progression in a real-world setting. Who this helps: This benefits vulnerable patients, particularly the elderly and those with pre-existing health conditions.

Plain English
This paper examines surgical site infections (SSIs), which are infections that occur after surgery and are becoming more common, especially due to antibiotic resistance and more complex patient conditions. The authors review various risk factors for SSIs and the latest methods for prevention and treatment, emphasizing the need to adapt strategies in light of bacteria that resist current antibiotics. Understanding and managing SSIs is crucial because these infections can lead to serious complications and longer hospital stays. Who this helps: This helps patients who undergo surgery and healthcare providers who care for them.

Plain English
This study looked at the differences in chest scans and lab results between patients infected with the Delta variant and those with the Alpha variant of COVID-19. They found that patients with the Delta variant had worse lung damage, with higher severity scores on CT scans, lower oxygen levels, and higher levels of inflammation markers in their blood. Specifically, Delta patients had a CT severity score that was notably worse compared to Alpha patients, indicating more severe lung involvement during the Delta surge. Who this helps: This helps patients and doctors by providing crucial information on how different COVID-19 variants affect lung health.

Plain English
This study looked at how certain blood test results and patient characteristics can help predict how sick patients with COVID-19 might get while in the hospital. They found that males with a high CRP level (over 60 mg/L) were more likely to need intensive care, and those with higher ASCL scores (a simple 11-point system based on age, gender, CRP, and LDH) had a much greater chance of dying—specifically, those with scores of 7 or more were at a significantly higher risk. This matters because it can help doctors identify patients who need more serious care early on, improving their chances of recovery. Who this helps: This helps doctors determine which COVID-19 patients need closer monitoring and urgent treatment.